Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development

Current Topics in Medicinal Chemistry

Volumn 5, Issue 10, 2005, Pages 1017-1029

  Goldstein, David M ^a   Gabriel, Tobias ^a  

^a Roche Palo Alto ^*  (United States)

Author keywords

IL 1 ; Interleukin 1; Kinase inhibitor; P38; P38 map kinase; Rheumatoid arthritis; TNF ; Tumor necrosis factor

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADENOSINE TRIPHOSPHATE; AMG 548; ANILINE DERIVATIVE; AZAINDOLE DERIVATIVE; BORTEZOMIB; CYTOKINE; DORAMAPIMOD; INDOLE DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 1BETA; KETONE DERIVATIVE; LIVER ENZYME; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN KINASE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; R 1487; RO 3201195; SCIO 323; SCIO 469; SD 06; SX 011; TAK 715; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702;

ACNE; AUTOIMMUNE DISEASE; CHILL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLAMMATION; LIVER DYSFUNCTION; MYALGIA; NEUROLOGIC DISEASE; NEUROTOXICITY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TACHYCARDIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27744582136     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054985939     Document Type: Review

References (44)

1. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
2. Feldmann, M. B.; Fionula, M.; Maini, Ravinder N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996, 14, 397-440.
3. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
4. Trejo, A.; Arzeno, H.; Browner, M. F.; Chanda, S.; Cheng, S.; Comer, D. D.; Dalrymple, S. A.; Dunten, P.; La Fargue, J.; Lovejoy, B.; Freire-Moar, J.; Lim, J.; McIntosh, J.; Miller, J.; Papp, E.; Reuter, D.; Roberts, R.; Sanpablo, F.; Saunders, J.; Song, K.; Villasenor, A.; Warren, S. D.; Welch, M.; Weller, P.; Whiteley, P. E.; Zeng, L.; Goldstein, D. M. Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase. J. Med. Chem. 2003, 46, 4702-4713.
5. Goldstein, D. M.; Alfredson, T.; Browner, M. F.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; La Fargue, J.; Lapierre, J. M.; Li, F.; McWeeney, D.; Papp, E.; Ramesha, C.; Roberts, R.; Rotstein, D.; Sanpablo, B. F.; So, O.-Y.; Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, T.; Weller, P.; Whiteley, P.; Young, K.; Zipfel, S. The Discovery of S-[5-Amino-1-(4-Fluoro-Phenyl)- 1H-Pyrazol-4-yl]-[3-(2, 3-Dihydroxy-Propoxy)-Phenyl]-Methanone, RO3201195, an Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase. Manuscript suhmitted for publication.
6. Ferraccioli, G. F. VX-745 Vertex Pharmaceuticals. Curr. Opin. Anti-Inflammat. Immunomodul. Investig. Drugs 2000, 2, 74-77.
7. Weisman, M.; Furst, D., Schiff, M.; Kauffman, R.; Merica, E. and Martin-Munley, S. FRI0018 A double-blind, placebo controlled trial of VX-745, an oral p38 MAPK inhibitor, in patients with rheumatoid arthritis (RA). Ann. Rheum. Dis. 2002, 61, Suppl. 1.
8. Vertex Press Release: www.vpharm.com, Cambridge, Sept. 24, 2001.
9. Braddock, M. Inflammation and Immune Diseases Drug Discovery and Development - Ninth Annual Summit (Part I); IDdb Meeting Report: Philadelphia, PA, 2005.
10. Vertex Press Release: www.vpharm.com, Rome, October 18, 2004.
11. Vertex Press Release: www.vpharm.com, Cambridge, June 10, 2005.
12. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Dugar, S.; Lu, Q.; Liang, X. Preparation of 5-[4-benzylpiperidinyl(piperazinyl)]-indolecarboxamides as inhibitors of p38 kinase. WO2000071535: November 30, 2000.
13. Lu, Q.; Mavunkel, B.; Chakravarty, S.; Perumattam, J.; Luedtke, G.; Chen, Z.; Xu, Y.-j.; Dugar, S.; Protter, A.; Schreiner, G.; Almirez, R.; Scott, B.; Laney, M.; Henson, M.; Lewicki, J.; Moore, A.; Lee, S.; Brahn, E.; Liu, D. Discovery and biological evaluation of p38α MAP kinase inhibitor SX-011. Abstracts of Papers, 228th ACS National Meeting; 2004, American Chemical Society, Philadelphia, PA, United States; pp. MEDI-217.
14. Nikas, S. N.; Drosos, A. A. SCIO-469 (Scios Inc). Curr. Opin. Investig. Drugs 2004, 5, 1205-1212.
15. Schreiner, G. Kinase Inhibitors: The next generation of anti-arthritic agents. Scios: Case study in their p38 kinase inhibitor program. Advances in Anti-Arthritic Agents, SMi Group, 2001.
16. Amakye, D. T. S.; Ward, C. Pharmacokinetics (PK) and pharmacodynamics (PD) OF SCIO-469, a p38 MAP kinase inhibitor. Clin. Pharmacol. Therap. 2004, 75, P3.
17. SPRiNG: SCIO-469 Patients with Rheumatoid Arthritis Not Receiving Methotrexate, www.clinicaltrials.gov, 2005.
18. Tong, S. E; Daniels, S. E.; Montano, T.; Chang, S.; Desjardins, P., SCIO-469, A novel p38 alpha MAPK inhibitor provides efficacy in acute post-surgical dental pain. Am. Soc. Clin. Pharmacol. Therapeut. Abstracts of papers 2004, 75, Abs PI-1.
19. Podar, K. H.; Teru, C. D.; Anderson, K. C. Targeting signalling pathways for the treatment of multiple myeloma. Exp. Opin. Therap. Targets 2005, 9, 359-391.
20. Schultz, R. M. Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog. Drug Res. 2003, 60, 59-92.
21. Navas, T; Hideshima, T.; Nguyen, A.; Henson, M.; Stebbins, L.; Kapoun, A. M.; O'Young, G.; Chakravarty, S.; Mavunkel, B.; Perumattam, J.; Luedtke, J.; Schreiner, G.; Anderson, K.; Higgins, L.S. The p38alpha MAPK inhibitor SCIO-469 enhances the apoptotic and anti-proliferative effects of proteasome inhibitors MG132 and PS341 (Velcade) in multiple myeloma cells. Proc. Am. Assoc. Cancer Res. 2004, 45.
22. Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma, www.clinicaltrials.gov, 2005.
23. Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma, www.clinicaltrials.gov, 2005.
24. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, Pier F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
25. Zimmiti, C. S.; Schwartz, R.; Torcellini, C. A.; Pargellis, C. A.; Madwed, J. B.; Weldon, S. M. Suppression of p38 activity in vitro and TNF alpha production in vivo with BIRB 796 BS, a novel p38 kinase inhibitor. Arhtritis & Rheumatism 2001, 44, S114.
26. Gupta, A.; Yong, C.-L.; Madwed, J. B.; Staehle, H.; Wood, C. C. Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of an Oral p38 MAP Kinase Inhibitor (BIRB 796 BS) in Healthy Human Males a Placebo-Controlled, Randomised Study, Double Blinded at Each Dose Level. J. Allergy and Clin. Immunol. 2002, Volume 109(1), (Supplement): 365-375.
27. Branger, J.; Van Den Blink, B.; Sebastiaan, W.; Madwed, J.; Bos, C. L.; Gupta, A.; Yong, C.-L.; Polmar, S. H., Olszyna, D. P.; Hack, E. C.; van Deventer, S. J. H.; Peppelenbosch, M. P. and van der Poll, T. Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia. J. Immunol. 2002, 168, 4070-4077.
28. Polmar, S. H.; Yong, C.-L.; Wood, C. C.; Staehle, H.; Gupta, A. Safety and Pharmacokinetics of an Oral p38 MAP Kinase Inhibitor (BIRB 796 BS), Administered Twice Daily for 14 Days to Healthy Volunteers. J Allergy Clin. Immunol. 2002, 109(1), (Supplement): 365-375.
29. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2002, 2, 1011-1020.
30. Wadsworth, S. A.; Cavender, D. E.; Beers, S. A.; Lalan, P.; Schafer, P. H.; Malloy, E. A.; Wu, W.; Fahmy, B.; Olini, G. C.; Davis, J. E.; Pellegrino-Gensey, J. L.; Wachter, M. P.; Siekierka, J. J. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Therapeut. 1999, 291, 680-687.
31. Parasrampuria, D. A; de Boer, P.; Desai-Krieger, D.; Chow, A. T.; Jones, C. R. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J. Clin. Pharmacol. 2003, 43, 406-413.
32. Fijen, J. W.; Zijlstra, J. G.; de Boer, Peter.; Spanjersberg, R,; Tervaert, J. W.; Cohen; Van Der Werf, T. S.; Ligtenberg, J. J. M.; Tulleken, J. E. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 2001, 124, 16-20.
33. Devraj, R. V. Discovery and development of orally active p38 kinase inhibitors as anti-TNF agents. Abstracts of Papers, 229th ACS National Meeting; 2005, American Chemical Society, San Diego, California, United States; pp. Medi-296.
34. Dominguez, C.; Liu, L.; Zhang, D.; Tamayo, N.; Powers, D.; Min, W.; Feige, F.; Harris, R.; Wild, S.; Neervannan, S.; Rashid, S.; Harvey, T. p-38, MAP-kinase: An exciting target for the treatment of Inflammatory Diseases. Abstract of papers, 228th ACS National Meeting; 2004, American Chemical Society, Philadelphia, PA, United States, pp. MEDI-189.
35. Spohr, U. D.; Malone, M. J.; Mantlo, N. B.; Zablocki, J. A. Preparation of arylpyrimidinones and analogs as drugs; WO9824780: June 11, 1998.
36. Tamayo, N.; Liao, L.; Goldberg, M.; Powers, D.; Tudor, Y.-Y.; Yu, V.; Wong, L. M.; Henkle, B.; Middleton, S.; Syed, R.; Harvey, T.; Jang, G.; Hungate, R.; Dominguez, C. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2005, 15, 2409-2413.
37. Claremon, D. A.; Ponticello, Gerald S. Preparation of azines as cytokine inhibitors.; WO2000031065: June 02, 2000.
38. Amgen press release: www.amgen.com, March 23, 2004.
39. Pharmacopeia press release: www.pharmacopeia.com, August 12, 2003.
40. Godfrey, J. D. Jr.; Hynes, J. Jr.; Dyckman, A. J.; Leftheris, K.; Shi, Z.; Wrobleski, S. T.; Doubleday, W. W.; Grosso, J. A. Methods for the preparation of pyrrolotriazinecompounds useful as kinase inhibitors; WO2004043912: May 27, 2004.
41. Leftheris, K.; Ahmed, G.; Chan, R.; Dyckman, A. J.; Hussain, Z.; Ho, K.; Hynes, J. Jr.; Letourneau, J.; Li, W.; Lin, S.; Metzger, A.; Moriarty, K. J.; Riviello, C.; Shimshock, Y.; Wen, J.; Wityak, J.; Wrobleski, S. T.; Wu, H.; Wu, J.; Desai, M.; Gillooly, K. M.; Lin, T. H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Zhang, R.; Diller, D.; Doweyko, A.; Sack, J.; Baldwin, J.; Barrish, J.; Dodd, J.; Henderson, I.; Kanner, S.; Schieven, G. L.; Webb, M. The Discovery of Orally Active Triaminotriazine Aniline Amides as Inhibitors of p38 MAP Kinase. J. Med. Chem. 2004, 47, 6283-6291.
42. Leftheris, K.; Hynes, J. Jr.; Dyckman, A.; Li, T.; Lin, S.; Wrobleski, S. T.; Wu, H.; Zhang, R.; Gillooly, K. M.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Doweyko, A.; Sack, J.; Barrish, J. C.; Dodd, J.; Schieven, G. L. Development of aniline amides containing alternative cores as orally active p38 MAP kinase inhibitors. Abstracts of Papers, 229th ACS National Meeting; 2005, San Diego, CA, United States; Medi-298.
43. Miwatashi, S.; Arikawa, Y.; Kotani, E.; Miyamoto, M.; Naruo, K.; Kimura, H.; Tanaka, T.; Asahi, S.; Ohkawa, S. Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715) as a potent and orally active anti-rheumatic agent. Abstracts of Papers, 229th ACS National Meeting; 2005, American Chemical Society, San Diego, CA, United States; pp. Medi-131.
44. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T. and Sundarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.